isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor

isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor
Trade Name
Orphan Indication Acute myeloid leukemia
USA Market Approval USA
USA Designation Date 2015-06-09 00:00:00
Sponsor Agios Pharmaceuticals, Inc.;88 Sidney Street;Cambridge, Massachusetts, 02139
Related Access Program
Children’s Hospital Los Angeles – Acute myeloid leukemia Jazz Pharmaceuticals – Secondary AML Celator Pharmaceuticals – Secondary AML University of California, San Francisco – Acute myeloid leukemia Emory University – Acute myeloid leukemia